Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Clinical trial NCT06745908 · RECRUITING
Trial details
- NCT number
- NCT06745908
- Sponsor
- ImmunityBio, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-01
- Primary completion
- 2028-09-01
- Enrollment
- 507
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.